Generics and Pharmaceuticals

///Generics and Pharmaceuticals

Why We May Lose Generic Drugs

The mood at the annual generic drug industry confab in Orlando in February was especially somber. The discussion during one panel was all about plunging drug prices, consolidation among drug-buying groups, and the increasingly cutthroat nature of the business. A top executive at Israel-based Teva Pharmaceutical Industries Ltd., the No. 1 supplier of generics in the U.S.,

Antiepileptic drugs increase risk of Alzheimer’s and dementia

The use of antiepileptic drugs is associated with an increased risk of Alzheimer's disease and dementia, according to a new study from the University of Eastern Finland and the German Center for Neurodegenerative Diseases, DZNE. Continuous use of antiepileptic drugs for a period exceeding one year was associated with a 15 percent increased risk of

2018-04-10T08:03:49+00:00 Tags: |

‘Coffee filter’ helps make new cancer drug Z-endoxifen 1000 times cheaper

Making drugs cheaper doesn’t always require pricey investments. A joint initiative by researchers from TU Eindhoven, the Dutch company Syncom BV and the Antoni van Leeuwenhoek hospital proves just that. What started out as a Bachelor project at TU/e laid the foundation for a much cheaper production of the promising cancer drug Z-endoxifen. Tamoxifen is

2018-04-07T09:19:19+00:00 Tags: |

Probe Into Generic Drug Price Fixing Set To Widen

Forty-five states and the Department of Justice are claiming that generic-drug prices are fixed and the alleged collusion may have cost U.S. business and consumers more than $1 billion. In their complaint, prosecutors say that when pharmacies asked drugmakers for their lowest price, the manufacturers would rig the bidding process. "The companies would work out

2018-03-31T06:40:05+00:00 Tags: |

Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation

The generic industry’s request for an SPC (supplementary protection certificates)  manufacturing waiver, which would allow them to produce in the EU SPC-protected drugs for other markets, does not influence or harm innovators’ rights, Marc–Alexander Mahl told EURACTIV.com in an interview. He said that the originators’ arguments for rejecting such a waiver and protecting their own rights

2018-03-31T06:17:23+00:00 Tags: |

Everyone wants to kill generic drug loophole — except drug makers and some GOP leaders

It’s so unpopular that lawmakers from both parties and President Trump’s top drug regulator want to kill it. But the pharmaceutical industry, flexing its powerful lobbying muscles, is successfully fighting back efforts to end a loophole that costs taxpayers and consumers billions of dollars a year. In recent years brand-name drug makers realized they could

Probe Into Generic Drug Price Fixing Set To Widen

Forty-five states and the Department of Justice are claiming that generic-drug prices are fixed and the alleged collusion may have cost U.S. business and consumers more than $1 billion. In their complaint, prosecutors say that when pharmacies asked drugmakers for their lowest price, the manufacturers would rig the bidding process. "The companies would work out in

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

When Teva Pharmaceuticals announced recently that it would begin selling a copycat version of Syprine — an expensive drug invented in the 1960s — the news seemed like a welcome development for people taking old drugs that have skyrocketed in price. Syprine, which treats a rare condition known as Wilson disease, gained notoriety after Valeant Pharmaceuticals

The pioneer of India’s biotech industry was denied her first job for being a woman

After failing the exam for medical school, Kiran Mazumdar-Shaw trained as a professional brewmaster. When no company in India’s male-dominated beer industry would hire her, despite her education and certification, she decided to start her own business developing industrial enzymes. Thirty years later, Mazumdar-Shaw is chairman and CEO of Biocon, India’s largest biotech company and

2018-02-15T11:13:50+00:00 Tags: |

Health system-led drug company unlikely to make a dent in drug prices, shortages

As four not-for-profit health systems unveiled plans to create their own generic drug company Thursday, experts say they'll face an uphill battle to make a significant dent in one of the fastest-growing industry expenses and persistent problems: rising drug prices and drug shortages. Intermountain Healthcare, Ascension, SSM Health and Trinity Health are working with the

2018-02-14T07:33:13+00:00 Tags: |

Kenya becomes first country to debut generic HIV drug

A new generic version of a frontline antiretroviral drug launches in Kenya today, the first time that HIV patients will have access to the more affordable version of the treatment. Dolutegravir, or DTG, will be available to patients through a partnership between the Kenyan Ministry of Health and Geneva-based Unitaid. DTG has been the preferred

2018-02-07T13:26:21+00:00 Tags: |

The power of pharma businesses to drive social change

Poverty, unemployment and inequality are perhaps the biggest challenges facing society today. These issues all urgently need solutions, and businesses bear a responsibility in helping to create them. One of the key ways in which businesses can do this is through Corporate Social Responsibility (CSR) programmes. Investing in CSR programmes can bring business as well

2018-01-31T09:40:26+00:00 Tags: |

Hospitals Launch Their Own Generic Drug Company

A consortium of four healthcare groups, citing frustration with ongoing shortages and high costs of generic medications, announced on Jan. 18, 2018 the formation of a not-for-profit generic drug company. The healthcare groups, Ascension, Intermountain Healthcare, SSM Health, and Trinity Health—working in consultation with the US Department of Veterans Affairs (VA)—represent more than 450 hospitals

2018-01-31T09:44:06+00:00 Tags: |

The story of Alvogen and the founding of a pharma empire

The pharmaceutical sector in the United States is undergoing a seismic shift. In recent years, generic pharmaceuticals, which are equivalent to branded drugs in everything apart from their price and name, have been expanding their share of the market at a rapid pace. At around 50 to 70 percent cheaper than their branded equivalents, more

Leading U.S. Health Systems Announce Plans to Develop a Not-for-Profit Generic Drug Company

To help patients by addressing the often unwarranted shortages and high costs of lifesaving generic medications, Intermountain Healthcare is leading a collaboration with Ascension, SSM Health and Trinity Health, in consultation with the U.S. Department of Veterans Affairs* (VA), to form a new, not-for-profit generic drug company. The five organizations represent more than 450 hospitals

Teva Pharmaceuticals Announces Launch of Generic HIV Drug

The US Department of Health & Human Services reports that 1.1 million individuals in the United States are living with HIV. Furthermore, in 2016, 39,782 individuals were diagnosed with the virus. The good news is, thanks to antiretroviral therapy, a HIV diagnosis no longer equates to a death sentence. Now, Teva Pharmaceuticals Industries Ltd. has announced that

FDA Commissioner on new steps to facilitate efficient generic drug review

The FDA today announced additional steps to encourage generic competition as part of our continued implementation of the Drug Competition Action Plan. This plan has three main components: reducing gaming by branded companies that can delay generic drug entry; resolving scientific and regulatory obstacles that can make it difficult to win approval of generic versions

2018-01-05T10:09:55+00:00 Tags: |

Do generic drugs compromise on quality?

You've no doubt seen them in the grocery store — typically drab-looking packages on the bottom shelf containing lower-priced generic versions of popular brand-name products. Some shoppers look at them with skepticism: Are they really as good? Or does cheaper just mean lower quality? Many people have the same questions about generic prescription medications, says

2018-01-02T08:39:22+00:00 Tags: |

Ruling Against Novartis Could Have Wider Implications for Generic Drug Labels

California's Supreme Court on Thursday ruled against Novartis in a decision that could have wider implications for whether brand-name or generic drugmakers should be held liable for warning consumers of risks in their drug labels. In a departure from other recent rulings, the highest California court found that a brand-name drug manufacturer's duty to warn

2018-01-02T08:32:34+00:00 Tags: |